How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors

From Investing Trends | Ad

According to Bloomberg NEF, changing the world to "All Green Energy" could cost about $173 trillion. And without this rare metal, going green would be IMPOSSIBLE. That's why there's a literal "gold rush" to find it. (HINT: It's not electric vehicles, nuclear power, or wind energy).

Show Me How This Industry Could Explode!

IKT Insider Trading (Inhibikase Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 55.80%

Insider Buying (Last 12 Months): $46,470.33

Insider Selling (Last 12 Months): $0.00

Inhibikase Therapeutics Insider Trading History Chart

Inhibikase Therapeutics Share Price & Price History

^$1.65

▼ -0.12 (-6.78%)

As of 12/3/2021 01:00 AM ET

Days: 30 | 90 | 365

Which State Is Ranked #1 For Lithium Investors?

From Investing Trends | Ad

The Fraser Institute ran a survey to find the best spot in the world for lithium mining. They researched 77 spots from around the world… and the Nevada Desert won the #1 spot by a landslide. And this small mining company just staked 11,700 acres of mineral claims in Nevada's hottest lithium spot...

See Why This Lithium Stock Could Explode

Inhibikase Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/17/2021	Milton H Werner	CEO	Buy	23,589	$1.97	$46,470.33

Insider Selling at Inhibikase Therapeutics?

Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Inhibikase Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Inhibikase Therapeutics (NYSE:IKT)

20.97% of Inhibikase Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Inhibikase Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/18/2021	Bank of New York Mellon Corp	39,580	$75K	0.0%	N/A	0.157%
11/16/2021	ACT Capital L.L.C.	1,010,000	$1.92M	1.0%	+15.4%	4.019%
11/16/2021	Warberg Asset Management LLC	26,000	$49K	0.0%	-71.1%	0.103%
11/16/2021	Millennium Management LLC	101,278	$0.19M	0.0%	N/A	0.403%
11/12/2021	Geode Capital Management LLC	25,833	$49K	0.0%	N/A	0.103%
11/10/2021	Goldman Sachs Group Inc.	27,895	$53K	0.0%	N/A	0.111%
11/9/2021	BlackRock Inc.	50,741	$96K	0.0%	+273.9%	0.202%
8/17/2021	Zeke Capital Advisors LLC	93,800	$0.26M	0.0%	+398.9%	0.926%
8/16/2021	Antara Capital LP	250,000	$0.70M	0.0%	N/A	2.467%
8/16/2021	Warberg Asset Management LLC	90,000	$0.25M	0.0%	N/A	0.888%
8/16/2021	Sabby Management LLC	421,200	$1.18M	0.2%	N/A	4.157%
8/13/2021	Altium Capital Management LP	109,749	$0.31M	0.1%	N/A	1.083%
8/13/2021	Murchinson Ltd.	320,947	$0.90M	0.3%	N/A	3.167%
8/13/2021	Vanguard Group Inc.	470,615	$1.32M	0.0%	N/A	4.644%
8/13/2021	FMR LLC	433,300	$1.21M	0.0%	+333.3%	4.276%
8/12/2021	Kepos Capital LP	700,000	$1.96M	0.1%	N/A	6.908%
5/21/2021	Citadel Advisors LLC	17,857	$0.11M	0.0%	N/A	0.178%
5/18/2021	Millennium Management LLC	11,224	$67K	0.0%	N/A	0.112%
5/18/2021	Citadel Advisors LLC	17,857	$0.11M	0.0%	N/A	0.178%
5/17/2021	HRT Financial LP	11,614	$69K	0.0%	N/A	0.115%

Data available starting January 2016

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It is also developing IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Today's Range

Now: $1.65

$1.54

$1.77

50 Day Range

MA: $1.94

$1.65

$2.17

52 Week Range

Now: $1.65

$1.54

$11.80

Volume

542,485 shs

Average Volume

360,914 shs

Market Capitalization

$41.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Inhibikase Therapeutics?: Inhibikase Therapeutics' top insider investors include:
Milton H Werner (CEO)
Who are the major institutional investors of Inhibikase Therapeutics?: Inhibikase Therapeutics' top institutional investors include:
ACT Capital L.L.C. — 4.02%
Millennium Management LLC — 0.40%
BlackRock Inc. — 0.20%
Bank of New York Mellon Corp — 0.16%
Goldman Sachs Group Inc. — 0.11%
Warberg Asset Management LLC — 0.10%
Which major investors are selling Inhibikase Therapeutics stock?: In the last quarter, IKT stock was sold by these institutional investors:
Warberg Asset Management LLC
Which major investors are buying Inhibikase Therapeutics stock?: In the last quarter, IKT stock was bought by institutional investors including:
ACT Capital L.L.C.
Millennium Management LLC
Bank of New York Mellon Corp
BlackRock Inc.
Goldman Sachs Group Inc.
Geode Capital Management LLC

Washington State's Legal Cannabis Stock Enjoying Explosive Growth

From All Marijuana Stocks | Ad

Nearly a decade ago, two ambitious entrepreneurs in the Seattle area saw the potential behind Washington State's referendum to legalize recreational use of cannabis. They created a company that has seen sales grow 8X since inception. Now they're poised to expand nationwide.

Get All the Details in Brand-New Special Report!